The American Heart Association/American Stroke Association (AHA/ASA) guidelines recommend using metformin with the addition of either a glucagon-like peptide-1 receptor agonist (GLP1) or sodium-glucose cotransporter 2 inhibitor (SGLT2) in patients with type 2 diabetes following stroke depending on other comorbid conditions, irrespective of hemoglobin A1C [35]. Here, GLP1R is linked to type 2 diabetes mellitus.